Andrew R. de Guttadauro
President at Oncolytics Biotech (U.S.), Inc.
Net worth: 11 037 $ as of 2024-05-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kirk Look | M | - |
Oncolytics Biotech (U.S.), Inc.
Oncolytics Biotech (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Oncolytics Biotech (US), Inc. is based in Half Moon Bay, CA. Part of Oncolytics Biotech, Inc., Oncolytics Biotech (US), Inc. is a company that manufactures pharmaceutical products. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ronald B. Moss | M | 64 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 3 years |
Mary Ann Dillahunty | F | - |
Oncolytics Biotech (U.S.), Inc.
Oncolytics Biotech (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Oncolytics Biotech (US), Inc. is based in Half Moon Bay, CA. Part of Oncolytics Biotech, Inc., Oncolytics Biotech (US), Inc. is a company that manufactures pharmaceutical products. | - |
Richard Kenney | M | 66 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andrew R. de Guttadauro
- Personal Network